Skip to main content

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

Collections open for submissions

First-in-human clinical trials for cancer and blood disorders

This series calls for clinical studies on novel agents for cancers and blood disorders. Summaries and reviews on first-in-human or first-in-class studies are also welcome.

The deadline for submissions is 31 October 2021.

How we treat

This series will focus on guidelines, consensus, and multidisciplinary approaches on cancers and blood disorders. All submissions to this series should be either invited or pre-approved. Prospective authors should contact the Journal Development Manager for pre-approval at The deadline for submissions is 31 October 2021.

New developments in delivery technology, materials, and molecular engineering for drug discovery

This series covers new technology, materials, and models for drug discovery. Development and applications of organoids, 3D cultures, PDX modes, nano-molecules, AI technology, and single-cell maps for drug discovery will be the focus. The deadline for submissions is 31 October 2021.

Thematic series

We are pleased to present two recent Journal of Hematology & Oncology thematic series:

Aims and scope

Journal of Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology. Read more.


Editor's quote

"Journal of Hematology & Oncology provides a forum for top-quality research and is a leading title in hematology and oncology, with an Impact Factor ranked in Q1 in both categories. The journal also publishes reviews and research highlights from leading experts in the field. Research is shared with fast turnaround times in an open access format among laboratory scientists, physician scientists, hematologists and oncologists."

Prof Delong Liu, Editor-in-Chief, Journal of Hematology & Oncology

Experimental Hematology & Oncology

Submit your research to our companion journal, Experimental Hematology & Oncology

Latest Tweets

Your browser needs to have JavaScript enabled to view this timeline

Annual Journal Metrics

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here